Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY5724886
Clazakizumab · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Clazakizumab Dose 1 | EXPERIMENTAL | Participants will receive clazakizumab subcutaneously (SC) |
| Clazakizumab Dose 2 | EXPERIMENTAL | Participants will receive clazakizumab SC |
| Clazakizumab Dose 3 | EXPERIMENTAL | Participants will receive clazakizumab SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Name | Type | Description |
|---|---|---|
| Clazakizumab | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * hsCRP ≥2 mg/L and ≤15 mg/L at screening * At least one of the following chronic conditions: * Established atherosclerotic cardiovascular disease (ASCVD) * Obesity (body mass index (BMI) ≥30 kg/m2) * Type 2 diabetes * Hypertension * Chronic kidney disease Grade 3 or ...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
Clazakizumab is being studied for atherosclerosis and cardiovascular disease in adults who have elevated hsCRP and are at increased risk for a cardiovascular event. The Phase 2 trial also enrolls people with obesity, hypertension, type 2 diabetes, or chronic renal insufficiency, conditions that raise cardiovascular risk.
Clazakizumab targets interleukin-6, or IL6. It is a monoclonal antibody that acts as an IL6 inhibitor. By binding IL6, the drug is designed to interfere with IL6 signaling, which is being studied in the context of inflammation and cardiovascular risk in atherosclerosis.
Clazakizumab is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The Phase 2 study is listed under the code LY5724886, reflecting Lilly's internal compound numbering.
Clazakizumab is in Phase 2 clinical development for atherosclerosis and cardiovascular risk. It is an investigational monoclonal antibody and has not been approved by the FDA for this use. The ongoing Phase 2 trial is currently recruiting participants.
Clazakizumab is being tested in the Phase 2 trial NCT07783802, titled A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event. The trial is recruiting 120 participants across the United States, Argentina, Japan, and Puerto Rico.
NCT07783802 is a randomized, double-blind, placebo-controlled Phase 2 study. It plans to enroll 120 adults aged 18 and older with elevated hsCRP and increased cardiovascular risk. Participants are not selected by biomarker beyond hsCRP, and healthy volunteers are excluded.